Nereus (Tradipitant): A New Paradigm in the Pharmacologic Management of Motion-Induced Emesis
On December 30, 2025, the U.S. Food and Drug Administration (FDA) approved Nereus (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion in adults[1]. This regulatory milestone marks the first novel pharmacologic intervention for…